Heparan sulfate – biosynthesis, structure and pathophysiological functions
- Time period:
- 1 January 2016 – 31 December 2018
- Project leader:
- Jin-ping Li
- Funder:
- Swedish Research Council
- Type of award:
- Project grant
- Total funding:
- 2,100,000 SEK
Heparan sulfate (HS) is expressed in the form of proteoglycan on the cell surface and in the extracellular matrix (ECM). Current studies have established the essential functions of HS in animal development, while future studies are more focused on its roles in pathogenesis of various diseases. The biological effects of HS are mainly through interactions with proteins including enzymes, growth factors/morphogens and their receptors, cytokines and ECM components. HS has a great diversity in molecular structures, which is a result of the complicated biosynthesis process involving multiple reactions catalyzed by modification enzymes. It is believed that activity of the enzymes controls biosynthesis of HS molecular structure; however, precise regulatory mode for the action of each enzyme remains obscure. As the structural property of HS is closely related to its function, elucidation of the regulatory machinery is of great importance for understanding HS biology. Thus, the general challenge in the field is to highlight the functional organization of the enzymes in HS biosynthesis and to explore the biological mechanisms of HS in development, homeostasis and pathological conditions.
Based the current progress and our recent findings, we have two major aims: 1) Investigate the regulatory mechanisms in HS biosynthesis and metabolism with focus on glucuronyl C5-epimerase (Hsepi); 2-O-sulfotransferase (2OST); 6-O-sulfotransferase (6OST) (these are modification enzymes) and heparanase (Hpa; an endo-glucuronidase specifically cleaves HS); 2) Find out the pathophysiological functions of HS and heparanase in diseases, e.g. Alzheimers disease (AD), inflammatory diseases and diabetes.
The first aim will be addressed by experiments in cell models. Three types of cells are used: a) MEF and stem cells isolated from the transgenic mice (Hsepi-KO, Hpa-KO, Hpa-tg); b) HEK293 cells stably overexpressing Hsepi, 2OST, 6OST and co-expressing the enzymes; c) CHO cell lines with defect in several enzymes for HS biosynthesis. Majority of the cell strains are established. Functional roles of the enzymes will be assessed through analysis of HS structures from each of the cell lines. Biological properties of the manipulated HS in these cells will be assessed by examination of cellular activity (e.g. signaling, proliferation). Essential techniques for analysis of HS and cell functions are established. Results of these studies (to be obtained in 1-2 years) will guide to design new experiments.
The second aim will be approached by experiments in mouse models. First step is to find out the implications of HS and heparanase in models of the diseases (AD, inflammation and diabetes). Development and pathological process of the diseases will be compared between the groups of Hpa-tg, Hpa-KO, AβPP and wildtype (WT) mice. The results will provide essential information for further exploring treatments for the diseases by targeting HS and heparanase. We will apply chemically modified heparin fragments (lacking anticoagulant activity) in the disease models. For AD, the hypothesis is that the fragments will prevent Aβ deposition. For RA and diabetic nephropathy (DN), we will evaluate the effect of heparanase inhibitors, as heparanase is upregulated in the tissues of these diseases. Though some pilot experiments are performed, in vivo studies are time-consuming, e.g. AD, the studies are designed for a period of 4 years.
Three PhD students and 1 postdoc are full time working on the described experiments. Collaborations are organized with international and national experts.
The results are expected to elucidate fundamental aspects of HS biology, specially the roles of HS and heparanase in the diseases. The novel knowledge obtained should be of great value to the increasing interest in developing drugs that selectively interfere HS-protein interactions. Applying heparin-derived heparanase inhibitors in the mouse disease models will provide principal information for conti